DiaMedica Therapeutics Net Income vs. Cash Flow From Operations
| DMAC Stock | USD 5.66 0.45 8.64% |
Net Loss | First Reported 2005-03-31 | Previous Quarter -5.1 M | Current Value -6.3 M | Quarterly Volatility 1.6 M |
For DiaMedica Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of DiaMedica Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well DiaMedica Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between DiaMedica Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of DiaMedica Therapeutics over time as well as its relative position and ranking within its peers.
DiaMedica |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
DiaMedica Therapeutics Cash Flow From Operations vs. Net Income Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining DiaMedica Therapeutics's current stock value. Our valuation model uses many indicators to compare DiaMedica Therapeutics value to that of its competitors to determine the firm's financial worth. DiaMedica Therapeutics is rated # 2 in net income category among its peers. It also is rated # 2 in cash flow from operations category among its peers . At present, DiaMedica Therapeutics' Net Loss is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the DiaMedica Therapeutics' earnings, one of the primary drivers of an investment's value.DiaMedica Cash Flow From Operations vs. Net Income
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
DiaMedica Therapeutics |
| = | (19.38 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
DiaMedica Therapeutics |
| = | (18.73 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
DiaMedica Cash Flow From Operations Comparison
DiaMedica Therapeutics is currently under evaluation in cash flow from operations category among its peers.
DiaMedica Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in DiaMedica Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, DiaMedica Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of DiaMedica Therapeutics' change in net profit over the period of time. It can combine multiple indicators of DiaMedica Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 6 K | 5.7 K | |
| Operating Income | -21.3 M | -20.2 M | |
| Income Before Tax | -19.3 M | -18.4 M | |
| Total Other Income Expense Net | 1.9 M | 2 M | |
| Net Loss | -19.4 M | -18.4 M | |
| Income Tax Expense | 43 K | 45.2 K | |
| Net Loss | -18 M | -17.1 M | |
| Net Loss | -12.2 M | -11.6 M | |
| Non Operating Income Net Other | 499.1 K | 461.3 K | |
| Net Interest Income | -1.1 K | -1.2 K | |
| Interest Income | 44.9 K | 47.1 K | |
| Change To Netincome | 1.8 M | 1.9 M | |
| Net Loss | (0.60) | (0.62) | |
| Income Quality | 0.97 | 1.05 | |
| Net Income Per E B T | 1.00 | 1.12 |
DiaMedica Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on DiaMedica Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of DiaMedica Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the DiaMedica Therapeutics' important profitability drivers and their relationship over time.
Use DiaMedica Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DiaMedica Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will appreciate offsetting losses from the drop in the long position's value.DiaMedica Therapeutics Pair Trading
DiaMedica Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to DiaMedica Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DiaMedica Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DiaMedica Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DiaMedica Therapeutics to buy it.
The correlation of DiaMedica Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DiaMedica Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DiaMedica Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DiaMedica Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your DiaMedica Therapeutics position
In addition to having DiaMedica Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Consumer Goods Thematic Idea Now
Consumer Goods
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Consumer Goods theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Goods Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Investing Opportunities. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
To fully project DiaMedica Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of DiaMedica Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include DiaMedica Therapeutics' income statement, its balance sheet, and the statement of cash flows.